News coverage about Accelerate Diagnostics (NASDAQ:AXDX) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Accelerate Diagnostics earned a news impact score of 0.17 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 46.9132364555519 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several research analysts recently commented on the company. ValuEngine upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, June 11th. BidaskClub upgraded Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research report on Thursday. Craig Hallum assumed coverage on Accelerate Diagnostics in a research report on Thursday, May 24th. They issued a “hold” rating and a $25.00 price target for the company. Finally, Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, May 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. Accelerate Diagnostics currently has an average rating of “Hold” and a consensus target price of $29.50.
Accelerate Diagnostics traded up $0.15, hitting $24.00, on Friday, according to Marketbeat. The company had a trading volume of 350,757 shares, compared to its average volume of 223,945. The firm has a market cap of $1.29 billion, a P/E ratio of -20.69 and a beta of 2.04. Accelerate Diagnostics has a 12-month low of $16.75 and a 12-month high of $30.45. The company has a current ratio of 27.80, a quick ratio of 26.44 and a debt-to-equity ratio of 0.65.
Accelerate Diagnostics (NASDAQ:AXDX) last announced its earnings results on Wednesday, May 9th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.05. Accelerate Diagnostics had a negative return on equity of 51.23% and a negative net margin of 1,568.29%. The business had revenue of $0.80 million during the quarter, compared to analyst estimates of $2.64 million. research analysts forecast that Accelerate Diagnostics will post -1.38 earnings per share for the current fiscal year.
In other Accelerate Diagnostics news, Director Jack W. Schuler bought 65,000 shares of the company’s stock in a transaction on Monday, May 14th. The stock was acquired at an average price of $19.97 per share, for a total transaction of $1,298,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack W. Schuler bought 100,000 shares of the company’s stock in a transaction on Friday, May 11th. The shares were acquired at an average price of $19.33 per share, with a total value of $1,933,000.00. The disclosure for this purchase can be found here. 49.30% of the stock is owned by insiders.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.